SGN-CD48A / Pfizer - LARVOL DELTA

A Safety Study of SGN-CD48A in Patients With Multiple Myeloma (clinicaltrials.gov) - P1; N=14; Terminated; Sponsor: Seattle Genetics, Inc.; Active, not recruiting ➔ Terminated; Due to overall benefit/risk profile

Clinical • Trial termination

A Safety Study of SGN-CD48A in Patients With Multiple Myeloma (clinicaltrials.gov) - P1; N=14; Active, not recruiting; Sponsor: Seattle Genetics, Inc.; Recruiting ➔ Active, not recruiting; N=85 ➔ 14; Trial completion date: Dec 2021 ➔ Oct 2019; Trial primary completion date: Aug 2020 ➔ Oct 2019

Clinical • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date